Clinical use of biologics for Crohn's disease in adults : lessons learned from real-world studies
INTRODUCTION: The therapeutic armamentarium for managing Crohn's disease (CD) has expanded significantly in recent decades. Several biologics with three different mechanisms of action [anti-tumor necrosis factor (TNF)-α, anti-integrin α4β7, and anti-IL 12/23] are currently available to manage CD.
AREA COVERED: This narrative review aims to summarize the most significant efficacy and safety data on the use of infliximab (IFX), adalimumab (ADA), vedolizumab (VDZ) and ustekinumab (UST) for the treatment of CD obtained from studies conducted in the real world (RW), compared to the results of randomized clinical trials (RCTs).
EXPERT OPINION: RW studies reported that biologic agents included in this analysis have higher remission rates and lower adverse event rates than findings from RCTs for treating patients with CD. All biological agents have proven effective and safe in RW studies, even when using biosimilars or switching to subcutaneous administration of the molecules for which they are available. Finally, anti-TNF-α agents, particularly IFX, have a higher rate of adverse events (AEs) than VDZ and UST. Therefore, patients at higher risk of AEs may benefit from other biologics than anti-TNF-α. However, further long-term RW studies are needed to confirm these findings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Expert opinion on biological therapy - 24(2024), 3 vom: 28. März, Seite 171-189 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tursi, Antonio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adalimumab |
|---|
| Anmerkungen: |
Date Completed 29.03.2024 Date Revised 29.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14712598.2024.2316180 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368110664 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368110664 | ||
| 003 | DE-627 | ||
| 005 | 20240330000909.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240207s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14712598.2024.2316180 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1355.xml |
| 035 | |a (DE-627)NLM368110664 | ||
| 035 | |a (NLM)38321868 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tursi, Antonio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical use of biologics for Crohn's disease in adults |b lessons learned from real-world studies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.03.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: The therapeutic armamentarium for managing Crohn's disease (CD) has expanded significantly in recent decades. Several biologics with three different mechanisms of action [anti-tumor necrosis factor (TNF)-α, anti-integrin α4β7, and anti-IL 12/23] are currently available to manage CD | ||
| 520 | |a AREA COVERED: This narrative review aims to summarize the most significant efficacy and safety data on the use of infliximab (IFX), adalimumab (ADA), vedolizumab (VDZ) and ustekinumab (UST) for the treatment of CD obtained from studies conducted in the real world (RW), compared to the results of randomized clinical trials (RCTs) | ||
| 520 | |a EXPERT OPINION: RW studies reported that biologic agents included in this analysis have higher remission rates and lower adverse event rates than findings from RCTs for treating patients with CD. All biological agents have proven effective and safe in RW studies, even when using biosimilars or switching to subcutaneous administration of the molecules for which they are available. Finally, anti-TNF-α agents, particularly IFX, have a higher rate of adverse events (AEs) than VDZ and UST. Therefore, patients at higher risk of AEs may benefit from other biologics than anti-TNF-α. However, further long-term RW studies are needed to confirm these findings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Crohn’s disease | |
| 650 | 4 | |a anti-TNF-α | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a ustekinumab | |
| 650 | 4 | |a vedolizumab | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a Adalimumab |2 NLM | |
| 650 | 7 | |a FYS6T7F842 |2 NLM | |
| 650 | 7 | |a Infliximab |2 NLM | |
| 650 | 7 | |a B72HH48FLU |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Ustekinumab |2 NLM | |
| 650 | 7 | |a FU77B4U5Z0 |2 NLM | |
| 700 | 1 | |a Mocci, Giammarco |e verfasserin |4 aut | |
| 700 | 1 | |a Del Gaudio, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Papa, Alfredo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on biological therapy |d 2001 |g 24(2024), 3 vom: 28. März, Seite 171-189 |w (DE-627)NLM116190124 |x 1744-7682 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:3 |g day:28 |g month:03 |g pages:171-189 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14712598.2024.2316180 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 3 |b 28 |c 03 |h 171-189 | ||